Wegovy Tablets

• Overview of oral Wegovy
• How does oral Wegovy work?
• How can a peptide drug be absorbed from a tablet?
• How should oral Wegovy be taken and what affects absorption?
• What do the clinical data show?
• Safety, interactions and practical considerations
• UK approval and the future of oral GLP-1 treatment

Prices of Oral Wegovy Tablets

Dosage/Quantity	Price
1.5 mg x 30 Tablets	£119.99
4.0 mg x 30 Tablets	£129.99
9.0 mg x 30 Tablets	£169.99
25.0 mg x 30 Tablets	£199.99

Discounts are available on repeat prescriptions.

How do I Buy Oral Wegovy Tablets?

To get started, please complete the free consultation on The Online Clinic website. Click on the button below and answer the questions for a doctor to review. A doctor will interact with you online before issuing the prescription. Your consultation is usually considered within 30 minutes if submitted between 8 am and 10 pm. Response times may be slower outside these hours.

Overview of oral Wegovy

Few medicines have risen to prominence quite as rapidly as semaglutide. Originally developed by the Danish pharmaceutical company Novo Nordisk as a treatment for type 2 diabetes, this GLP-1 receptor agonist has become one of the pharmaceutical success stories of the decade. Its ability not only to improve glucose control but also to reduce appetite and produce substantial weight loss transformed the drug from a diabetes treatment into a global phenomenon.

The injectable forms are now familiar names. Ozempic® is used in type 2 diabetes, while Wegovy® was developed specifically for chronic weight management. Demand for GLP-1 medicines has subsequently soared, accompanied by extraordinary levels of media attention and public interest. Semaglutide has become that unusual thing: a prescription medicine whose brand names have entered everyday conversation.

It is worth distinguishing oral Wegovy from Rybelsus® here. Rybelsus was the original oral formulation of semaglutide, developed and licensed for the treatment of type 2 diabetes. Oral Wegovy uses the same active ingredient, semaglutide, but is the higher-dose formulation licensed for chronic weight management and follows a different dosing regimen. The two products are therefore closely related, but they are not interchangeable brand names for the same indication or dose.

There is an interesting scientific twist to this success. Semaglutide is a peptide, and peptides generally make poor tablets. Swallowed peptides face an extremely hostile journey: they can be degraded in the gastrointestinal tract and, even if they survive, their size and polarity make it difficult for them to cross biological membranes. This is why peptide medicines have traditionally been given by injection.

Millions of people have nevertheless been willing to inject semaglutide once a week. The obvious question is: could the injection be replaced by a tablet?

That question brings us to oral Wegovy.

Wegovy tablets contain the same active drug, semaglutide, as the familiar once-weekly Wegovy injection. The important difference is the route of administration: oral Wegovy delivers a peptide medicine as a once-daily tablet. In June 2026, the MHRA authorised Wegovy tablets in the UK for weight management in adults with obesity (BMI ≥30 kg/m²), or overweight (BMI ≥27 to <30 kg/m²) with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity.²

Treatment starts at 1.5 mg once daily, followed by dose-escalation steps of 4 mg, 9 mg and 25 mg, with at least one month at each dose level. The recommended maintenance dose is 25 mg once daily.

Getting semaglutide into a tablet, however, is not simply a matter of putting the injectable drug into a pill. It requires overcoming a problem that has challenged the pharmaceutical industry for decades: how do you persuade the gastrointestinal tract to absorb a peptide?

How does oral Wegovy work?

Semaglutide is an analogue of the naturally occurring incretin hormone GLP-1. It activates the GLP-1 receptor, including pathways involved in appetite and energy intake, helping people feel fuller, reducing hunger and food cravings, and lowering calorie intake. It also stimulates glucose-dependent insulin secretion and suppresses glucagon when blood glucose is elevated. The pharmacological mechanism is therefore the same whether semaglutide is given by tablet or injection.

Semaglutide has a plasma half-life of approximately one week. This unusually long persistence is important for the oral formulation: daily dosing allows exposure to accumulate and helps smooth out the substantial day-to-day variation in how much drug is absorbed from an individual tablet.

How can a peptide drug be absorbed from a tablet?

Peptides present two major problems when swallowed. They can be broken down by the acidic, enzyme-rich environment of the gastrointestinal tract, and their large, polar structures cross biological membranes poorly. Oral Wegovy solves part of this problem by co-formulating semaglutide with salcaprozate sodium, better known as SNAC (sodium N-(8-[2-hydroxybenzoylamino) caprylate).

Unlike most conventional tablets, which are mainly absorbed through the small intestine, semaglutide is absorbed predominantly through the stomach. SNAC acts locally around the dissolving tablet and facilitates movement of semaglutide across the gastric epithelium. Mechanistic work with oral semaglutide indicates that the local environment created by SNAC helps protect semaglutide from proteolytic degradation and favours transcellular absorption.

The efficiency is still remarkably low. The UK product information estimates absolute oral bioavailability at only about 1–2%. Nevertheless, the 25 mg tablet produces an average steady-state semaglutide concentration of about 77 nmol/L in people with overweight or obesity—very similar to the approximately 75 nmol/L reported with the 2.4 mg weekly injection. Oral exposure is, however, considerably more variable.

How should oral Wegovy be taken and what affects absorption?

The dosing instructions are not simply a matter of convenience; they are part of the formulation strategy. Wegovy tablets should be taken after a fasting period of at least eight hours, swallowed whole with no more than 120 mL of water, and followed by a wait of at least 30 minutes before food, drink or other oral medicines.

• Food decreases absorption of oral semaglutide.
• Larger volumes of water reduce absorption compared with smaller volumes.
• Waiting less than 30 minutes before eating, drinking or taking another medicine decreases semaglutide absorption.
• Longer pre- and post-dose fasting periods increase absorption.
• Taking several other tablets at the same time can reduce semaglutide exposure; in one pharmacokinetic study, co-administration with five tablets reduced semaglutide AUC by 34% and Cmax by 32%.

What do the clinical data show?

The pivotal study for the 25 mg oral formulation was OASIS 4, a randomised, double-blind, placebo-controlled phase 3 trial involving 307 adults with obesity or overweight plus at least one weight-related comorbidity.³ People with diabetes were excluded. Participants received once-daily oral semaglutide 25 mg or placebo, together with reduced-calorie diet and increased physical activity, for 64 weeks.

The trial was designed to ask a practical question: how much additional weight loss does the tablet produce when added to the same diet and activity advice given to the placebo group? The headline figure, a 13.6% average reduction in body weight, means that someone starting at 100 kg would have lost about 13.6 kg on average by week 64. The placebo group also lost some weight (2.2%), reflecting the effect of lifestyle measures and participation in the trial.

Key findings from OASIS 4

• Mean body-weight change at week 64: −13.6% with oral semaglutide 25 mg versus −2.2% with placebo (treatment-policy analysis).
• Assuming participants remained on treatment without additional anti-obesity therapy, estimated weight change was −16.6% versus −2.8% with placebo.
• 76.3% achieved ≥5% weight loss versus 30.5% with placebo.
• 59.8% achieved ≥10% weight loss versus 14.1% with placebo.
• 47.0% achieved ≥15% weight loss versus 5.4% with placebo.
• 27.5% achieved ≥20% weight loss versus 3.0% with placebo.

The percentage thresholds help show how widely responses varied. Nearly half of participants taking oral semaglutide lost at least 15% of their starting weight, and more than a quarter lost at least 20%. These are substantial reductions, but they also make clear that not everyone responds to the same extent.

The two weight-loss estimates above answer slightly different questions. The 13.6% figure reflects the overall trial experience, including people who stopped treatment or used other weight-management approaches. The larger 16.6% estimate is intended to show the effect if participants had remained on treatment without additional anti-obesity therapy. For a general reader, the 13.6% figure is therefore the more useful headline result.

Safety, interactions and practical considerations

The safety profile of oral Wegovy is broadly consistent with the established GLP-1 receptor agonist class. In OASIS 4, gastrointestinal adverse effects were common and occurred most often during dose escalation. Nausea occurred in 46.6% of semaglutide-treated participants, vomiting in 30.9%, constipation in 20.1% and diarrhoea in 17.6%. Gastrointestinal events led to permanent treatment discontinuation in 3.4%.

The oral formulation also creates some specific practical interaction issues. Semaglutide delays gastric emptying and may alter absorption of other oral medicines. Levothyroxine exposure increased by 33% in a pharmacokinetic study, so thyroid monitoring should be considered when the drugs are used together. Frequent INR monitoring is recommended when semaglutide is initiated in patients taking warfarin or other coumarin anticoagulants. No clinically relevant exposure changes were seen with digoxin, combined oral contraceptives, metformin or furosemide. The most important general rule remains to wait at least 30 minutes after oral Wegovy before taking other tablets.

This is not a complete account of contraindications and precautions; prescribers should consult the current Summary of Product Characteristics, particularly regarding pancreatitis, dehydration, diabetic retinopathy, pregnancy and concomitant glucose-lowering treatment.

UK approval and the future of oral GLP-1 treatment

The MHRA approved Wegovy tablets for weight management on 11 June 2026,¹ making them the first GLP-1 receptor agonist tablet authorised for weight loss in the UK. At the time of approval, the MHRA stated that the treatment was not yet available through the NHS; NHS use is subject to the usual health-technology assessment and commissioning processes.

Oral Wegovy is scientifically important for a reason that extends beyond obesity treatment. It demonstrates that a peptide with very low oral bioavailability can still become a clinically effective tablet when potency, pharmacokinetics and formulation technology are matched appropriately. The contrast with emerging non-peptide oral GLP-1 agonists such as orforglipron is particularly interesting: one approach makes a peptide absorbable, while the other redesigns the drug so that peptide-delivery technology is no longer required.

References:

1. MHRA: First GLP-1 tablet for weight loss approved in the UK. 11 June 2026:
   https://www.gov.uk/government/news/first-glp-1-tablet-for-weight-loss-approved-in-the-uk
2. Wegovy 25 mg tablets: Summary of Product Characteristics.
   https://www.medicines.org.uk/emc/product/102347/smpc
3. OASIS 4: Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity, S. Wharton et al. N Engl J Med. 2025, 393: 1077–1087; doi: 10.1056/NEJMoa2500969.
4. OASIS 1: Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1), F. Knop et al. Lancet. 2023, 402, 705–712.
5. STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity, J. Wilding et al., N. Engl. J Med. 2021, 384, 989–1002; doi:10.1056/NEJMoa2032183.
6. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist, S. Buckley et al. Sci. Transl. Med. 2018, 10: eaar7047; doi: 10.1126/scitranslmed.aar7047.

Plain-English guide to technical and clinical terms